MXPA05012705A - Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral. - Google Patents

Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.

Info

Publication number
MXPA05012705A
MXPA05012705A MXPA05012705A MXPA05012705A MXPA05012705A MX PA05012705 A MXPA05012705 A MX PA05012705A MX PA05012705 A MXPA05012705 A MX PA05012705A MX PA05012705 A MXPA05012705 A MX PA05012705A MX PA05012705 A MXPA05012705 A MX PA05012705A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
active ingredient
receptor antagonist
tnfalpha
inhibitor
Prior art date
Application number
MXPA05012705A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Boughtonsmith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312321A external-priority patent/GB0312321D0/en
Priority claimed from SE0301655A external-priority patent/SE0301655D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05012705A publication Critical patent/MXPA05012705A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA05012705A 2003-05-29 2004-05-27 Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral. MXPA05012705A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312321A GB0312321D0 (en) 2003-05-29 2003-05-29 New combination
SE0301655A SE0301655D0 (sv) 2003-06-05 2003-06-05 New combination
PCT/SE2004/000817 WO2004105798A1 (en) 2003-05-29 2004-05-27 A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α

Publications (1)

Publication Number Publication Date
MXPA05012705A true MXPA05012705A (es) 2006-02-08

Family

ID=33492248

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012705A MXPA05012705A (es) 2003-05-29 2004-05-27 Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.

Country Status (15)

Country Link
US (1) US20070032465A1 (https=)
EP (1) EP1633401A1 (https=)
JP (1) JP2007501270A (https=)
KR (1) KR20060037258A (https=)
AR (1) AR044452A1 (https=)
BR (1) BRPI0410739A (https=)
CA (1) CA2526883A1 (https=)
CO (1) CO5640094A2 (https=)
IS (1) IS8188A (https=)
MX (1) MXPA05012705A (https=)
NO (1) NO20056131L (https=)
RU (1) RU2350354C2 (https=)
TW (1) TW200507829A (https=)
UY (1) UY28335A1 (https=)
WO (1) WO2004105798A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2006095355A1 (en) * 2005-03-07 2006-09-14 Ganga Raju Gokaraju Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US9538710B2 (en) 2010-04-01 2017-01-10 Tony Wayne Covely Crop product tracking system and method
US10444122B2 (en) 2010-04-01 2019-10-15 Agri-Labs Holdings Llc Soil sample tracking system and method
CN103841969A (zh) * 2011-08-04 2014-06-04 美国卫生和人力服务部 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
EP0952832B1 (en) * 1996-05-20 2008-08-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CN1147483C (zh) * 1999-04-09 2004-04-28 阿斯特拉曾尼卡有限公司 金刚烷衍生物
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US8058441B2 (en) * 2001-07-02 2011-11-15 N.V. Organon Tetrahydroquinoline derivatives
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
KR20060037258A (ko) 2006-05-03
US20070032465A1 (en) 2007-02-08
CA2526883A1 (en) 2004-12-09
RU2005136131A (ru) 2006-07-27
CO5640094A2 (es) 2006-05-31
WO2004105798A1 (en) 2004-12-09
IS8188A (is) 2005-12-20
AU2004243137A1 (en) 2004-12-09
AR044452A1 (es) 2005-09-14
RU2350354C2 (ru) 2009-03-27
JP2007501270A (ja) 2007-01-25
UY28335A1 (es) 2004-12-31
TW200507829A (en) 2005-03-01
EP1633401A1 (en) 2006-03-15
BRPI0410739A (pt) 2006-06-27
NO20056131L (no) 2006-02-28

Similar Documents

Publication Publication Date Title
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
NO20060128L (no) Krystallinske tumornekrosesfaktor reseptor 2-polypeptider
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
NO20072595L (no) 3-arylaminopyridinderivater
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
EP2277512A3 (en) Pharmaceutical compositions and dosage forms of thalidomide
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
TW200510416A (en) P38 inhibitors and methods of use thereof
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
SE0101932D0 (sv) Pharmaceutical combinations
NO20044898L (no) Nye etonogestrel estere
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
SE0300445D0 (sv) New combination
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
EP2323655A4 (en) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal